Matthew Hoermann, MD
Family Medicine · Fredericksburg, TXNPI 1790770634
Payments from drug & device makers
Across 324 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$551
- GSK$380
- Novo Nordisk$353
- Amgen$349
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$308
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,39697%
- Education$1503%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 82 | $1,303 |
| Lilly USA, LLC | 36 | $551 |
| GSK | 23 | $380 |
| Novo Nordisk | 21 | $353 |
| Amgen | 21 | $349 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $308 |
| Astellas Pharma US Inc | 8 | $257 |
| Amarin Pharma, Inc. | 12 | $244 |
| AstraZeneca | 11 | $190 |
| Pfizer | 10 | $173 |
| Otsuka America Pharmaceutical, Inc. | 10 | $172 |
| Johnson & Johnson | 9 | $153 |
| Exact Sciences | 7 | $133 |
| Merck | 6 | $106 |
| Inspire Medical Systems, Inc. | 4 | $94 |
| Sanofi Pasteur Inc. | 4 | $90 |
| Boehringer Ingelheim | 5 | $76 |
| Genentech USA, Inc. | 4 | $71 |
| Kowa Pharmaceuticals America, Inc. | 4 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| Abbott | 2 | $48 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| Shield Therapeutics Inc | 2 | $32 |
| Bayer | 2 | $31 |
| Alk-abello, Inc | 1 | $30 |
| Novartis | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Evofem Biosciences, Inc. | 1 | $21 |
| Boston Scientific | 1 | $19 |
| Medtronic | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Photonicare Inc | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| Exeltis, USA Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$125
How this compares
$5,546 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 128 | $119,823 |
| FarxigaDapagliflozin Propanediol | 97 | $66,559 |
| JardianceEmpagliflozin | 46 | $52,520 |
| EliquisApixaban | 54 | $47,860 |
| MounjaroTirzepatide | 39 | $43,801 |
| JanuviaSitagliptin Phosphate | 30 | $33,408 |
| XareltoRivaroxaban | 35 | $28,509 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $23,439 |
| TrulicityDulaglutide | 15 | $21,192 |
| RexultiBrexpiprazole | 14 | $17,321 |
| MyrbetriqMirabegron | 28 | $16,688 |
| RybelsusSemaglutide | 15 | $14,396 |
| TradjentaLinagliptin | 27 | $14,037 |
| LinzessLinaclotide | 21 | $10,535 |
| Repatha SureclickEvolocumab | 13 | $7,883 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $353 | $134,219143 claims |
| AstraZenecaFarxiga | $190 | $66,55997 claims |
| Boehringer IngelheimJardiance, Tradjenta | $76 | $66,55773 claims |
| Lilly USA, LLCMounjaro, Trulicity | $551 | $64,99354 claims |
| PfizerEliquis | $173 | $47,86054 claims |
| MerckJanuvia | $106 | $33,40830 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $380 | $30,61751 claims |
| Johnson & JohnsonXarelto | $153 | $28,50935 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $172 | $17,32114 claims |
| Astellas Pharma US IncMyrbetriq | $257 | $16,68828 claims |
| AbbVieLinzess, Lumigan | $1,303 | $13,77233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Fredericksburg
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.